313,559 Shares in Dyne Therapeutics, Inc. $DYN Acquired by University of Wisconsin Foundation

Key Points

• University of Wisconsin Foundation acquired 313,559 Dyne Therapeutics shares worth approximately $6.96 million, making DYN about 5.5% of its portfolio. Institutional investors collectively own 96.68% of the company.
• Analyst sentiment remains generally positive, with a consensus rating of “Moderate Buy” and an average price target of $34.42, although targets range from $24 to $45 and one service issued a “Strong Sell” rating.
• Dyne shares opened at $25.99, near their 52-week high, while the company reported a quarterly loss of $1.08 per share—worse than the $0.75 loss analysts expected. Separately, director Jason P. Rhodes sold 2.16 million shares for about $54 million.

University of Wisconsin Foundation bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 313,559 shares of the company's stock, valued at approximately $6,964,000. Dyne Therapeutics makes up approximately 5.5% of University of Wisconsin Foundation's investment portfolio, making the stock its 9th biggest holding. University of Wisconsin Foundation owned about 0.17% of Dyne Therapeutics as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. grew its position in shares of Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock valued at $343,085,000 after purchasing an additional 14,727,667 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Dyne Therapeutics in the second quarter worth $275,500,000. Orbis Allan Gray Ltd purchased a new stake in shares of Dyne Therapeutics in the fourth quarter worth $93,926,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Dyne Therapeutics in the second quarter worth $30,378,000. Finally, Perceptive Advisors LLC boosted its stake in Dyne Therapeutics by 543.7% during the fourth quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company's stock valued at $68,048,000 after buying an additional 2,938,500 shares during the period. 96.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

DYN has been the subject of several recent analyst reports. Sanford C. Bernstein boosted their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a "market perform" rating in a research report on Wednesday, May 13th. Royal Bank Of Canada raised their price target on Dyne Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a report on Thursday, July 30th. Wall Street Zen downgraded Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 1st. Morgan Stanley cut their price objective on Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating for the company in a report on Friday, July 31st. Finally, Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a research report on Friday, May 15th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $34.42.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 2,160,516 shares of the business's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the sale, the director directly owned 428,946 shares of the company's stock, valued at $10,723,650. The trade was a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian S. Posner purchased 2,500 shares of the stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average cost of $17.48 per share, with a total value of $43,700.00. Following the completion of the purchase, the director directly owned 22,500 shares of the company's stock, valued at $393,300. The trade was a 12.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders sold 4,139,196 shares of company stock worth $99,449,852. 9.46% of the stock is owned by corporate insiders.

Dyne Therapeutics Stock Down 0.4%

Shares of DYN opened at $25.99 on Tuesday. The firm has a market cap of $4.85 billion, a P/E ratio of -7.80 and a beta of 1.07. The stock has a 50 day simple moving average of $23.83 and a two-hundred day simple moving average of $19.83. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. Dyne Therapeutics, Inc. has a 1 year low of $11.92 and a 1 year high of $27.31.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.33). On average, analysts forecast that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current fiscal year.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source